Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Carrie Cummings"'
Autor:
Marie Bleakley, Ralph Graeme Black, David Wu, Melinda Ann Biernacki, Jessica Lok, Kimberly A Foster, Carrie Cummings, Kyle B Woodward, Tim Monahan, Vivian G Oehler, Derek L Stirewalt, Anthony Rongvaux, Hans Joachim Deeg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Myelodysplastic syndromes (MDS) arise from somatic mutations acquired in hematopoietic stem and progenitor cells, causing cytopenias and predisposing to transformation into secondary acute myeloid leukemia (sAML). Recurrent mutations in sp
Externí odkaz:
https://doaj.org/article/f4118942bcee4419aa80630b09b59a98
Autor:
Kyle B. Woodward, Kimberly A. Foster, Soheil Meshinchi, Michael E. Coon, Elihu H. Estey, Tanya Cunningham, Tayla M Olsen, Kelda M. Gardner, Jamie Stokke, Melinda A. Biernacki, Robson G. Dossa, Marie Bleakley, Anthony Rongvaux, Michelle Brault, Carrie Cummings
Publikováno v:
J Clin Invest
The tight junction protein claudin-2 is upregulated in disease. Although many studies have linked intestinal barrier loss to local and systemic disease, these have relied on macromolecular probes. In vitro analyses show, however, that these probes ca
Autor:
Carrie Cummings, Vivian G. Oehler, Stephanie Busch, Sergei Doulatov, Courtnee Clough, Melinda Ann Biernacki, Kimberly A. Foster, Derek L. Stirewalt, Marie Bleakley
Publikováno v:
Blood. 136:13-14
Myeloid malignancies are susceptible to immunologic destruction but antigen-specific T cell immunotherapies for these diseases are currently limited. Immunotherapies targeting neoantigens created from recurrent protein-coding mutations should selecti
Autor:
Jerald P. Radich, Marc A. Unger, Neil P. Shah, Ramesh Ramakrishnan, Stephanie G. Willis, Geoff Facer, Michael W. Deininger, Frank McCormick, Vivian G. Oehler, Carrie Cummings, Jian Qin, Antoine Daridon, Suchitra Ananthnarayan
Publikováno v:
Leukemia. 23:396-399
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR
Autor:
Laura Johnston, Stephen J. Forman, Su Chu, Vivian G. Oehler, Robert S. Negrin, David S. Snyder, Jerald P. Radich, Carrie Cummings, Allen Lin, Ted Gooley, Frederick R. Appelbaum, Ravi Bhatia
Publikováno v:
Blood. 109:1782-1789
The impact of imatinib mesylate (IM) treatment for chronic myeloid leukemia (CML) on subsequent allogeneic transplantation is uncertain. To better understand this relationship, we retrospectively compared 145 patients with CML receiving IM for a mini
Publikováno v:
Blood. 126:3641-3641
Acute myeloid leukemia (AML) is a heterogeneous disease that develops secondary to the acquisition of mutations that disrupt cell differentiation, proliferation and survival. MicroRNAs (miRNAs or miRs) are short non-coding RNA molecules that modulate
Publikováno v:
Blood. 124:3541-3541
Acute myeloid leukemia (AML) is characterized by increased self-renewal of leukemia stem/progenitor cells and failure of differentiation to mature myeloid cells. MicroRNAs (miRNAs, miRs) are short non-coding RNAs whose power stems from the ability to
Publikováno v:
Blood. 124:874-874
Background: Acute myeloid leukemia (AML) is characterized by increased self-renewal of leukemia stem/progenitor cells and failure of differentiation to mature myeloid cells. MicroRNAs (miRNAs) are small single stranded non-coding RNAs 19 to 24 nucleo
Autor:
Brent L. Wood, Carrie Cummings, Derek L. Stirewalt, Roland B. Walter, Vivian G. Oehler, Min Fang, Olga Sala-Torra, Jerald P. Radich
Publikováno v:
Blood. 116:2743-2743
Abstract 2743 CD52 is a cell surface glycoprotein of unknown function that is expressed in B and T lymphocytes, macrophages, and monocytes, but is not expressed in normal hematopoietic stem/progenitor cells. CD52 is also expressed in chronic lymphocy
Autor:
Kathleen M. Sabo, Jerald P. Radich, Paula A. Ladne, Derek L. Stirewalt, Brent L. Wood, Era L. Pogosova-Agadjanyan, Vivian G. Oehler, Katherine A. Guthrie, Carrie Cummings, Ted Gooley, Janis L. Abkowitz
Publikováno v:
Blood. 112:1071-1071
PRAME, or the Preferentially Expressed Antigen in Melanoma, is an attractive therapeutic target in cancer treatment. It has been described as a tumor-associated antigen and more recently as a co-repressor of retinoic acid signaling in the presence of